DexCom, Inc. found using ticker (DXCM) now have 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 200 and 125 with the average target price sitting at 176.88. With the stocks previous close at 163.59 this now indicates there is a potential upside of 8.1%. The 50 day MA is 151.66 and the 200 day MA is 136.83. The market capitalisation for the company is $15,345m. Find out more information at: http://www.dexcom.com
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.